In this episode, we sit down with Ben Holmes (Co-Founder & CEO) and Dr. Nathan J. Castro (Co-Founder & CTO) of Nanochon, a medical device company reimagining orthopedic care with next-generation 3D-printed cartilage repair implants. Their mission is bold yet simple: to create implants that not only replace damaged cartilage but also encourage the body to regenerate it. Ben and Nathan take us behind the scenes of Nanochon’s journey, from early-stage research and engineering breakthroughs to achieving Health Canada approval for the company’s first-in-human clinical trial of its knee implant. Along the way, they unpack the unique biomechanics behind their design, the balance between mechanical stability and biological regeneration, and why their device could one day shift the standard of care in orthopedic repair. This conversation addresses the real-world challenges of translating lab-based innovations into regulated medical devices, including fundraising, navigating ISO 13485 quality standards, refining design iterations, and preparing for clinical adoption. It’s part science, part entrepreneurship, and entirely about impact. Together, they show how startups can bridge the gap between research and patient outcomes.
⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute medical or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a licensed professional.
About Our Guests
Ben Holmes is the Co-Founder and CEO of Nanochon. With a background in biomedical engineering, company formation, and early-stage executive leadership, he has dedicated his career to translating research into viable medical device companies. Ben earned his B.S. from the University of Virginia and his Ph.D. in biomedical engineering from George Washington University. At Nanochon, he leads strategic growth, fundraising, and commercialization, working to bring regenerative cartilage implants from concept to clinic.
Dr. Nathan J. Castro is the Co-Founder and CTO of Nanochon. A biomedical engineer and entrepreneur, he holds a Ph.D. in Tissue Engineering and Regenerative Medicine from George Washington University, along with a Master’s in Biomedical Engineering and a B.A. in Chemistry from the University of Texas at El Paso. Nathan specializes in medical device design, regulatory approval, ISO13485 compliance, and intellectual property development. At Nanochon, he oversees early-stage development programs, bridging biomechanics, regenerative science, and clinical translation.
Key Takeaways
- Nanochon is developing a 3D-printed knee implant that not only replaces cartilage but also actively promotes the growth of natural tissue.
- The implant is biomechanically tuned, providing immediate stability for patients while creating an environment for cartilage regeneration.
- Nanochon recently received Health Canada approval to conduct its first-in-human clinical trial, a significant step toward clinical adoption.
- The team has overcome hurdles in design, regulatory clearance, fundraising, and quality management systems as a young company in the medical device space.
- Their long-term goal is to establish a new clinical standard in orthopedic repair that could delay or eliminate the need for total knee replacements.
The Problem with Cartilage Repair
- Traditional methods like microfracture surgery, autografts, or donor grafting are invasive, inconsistent, and often lack durability.
- Many patients face reduced mobility, recurring pain, or eventual progression to full joint replacement.
- Nanochon’s implant offers a regenerative, less invasive alternative designed to extend joint life and restore mobility earlier in the disease process.
How the Implant Works
- Fabricated using advanced 3D printing materials, the implant mimics the mechanical behavior of cartilage.
- Provides structural support while encouraging biological remodeling and tissue ingrowth over time.
- The design uniquely balances immediate function with long-term regeneration, addressing both short-term stability and future tissue health.
Nanochon’s Journey
- Founded with a mission: address the unmet need for durable, regenerative cartilage repair.
- R&D focus: years of prototyping and material testing to ensure biomechanical integrity and biological compatibility.
- Regulatory progress: obtained Health Canada approval for a first-in-human trial, validating the safety and design of the implant.
- Commercialization strategy: raised capital, built IP protections, and established ISO13485 quality standards for scaling production.
- Looking forward: expanding clinical trials, refining design through real-world feedback, and preparing for broader regulatory submissions.
Future Outlook
- Success in clinical trials could reshape orthopedic practice, giving patients a regenerative option before joint replacement.
- The technology may extend beyond the knee to address ankles, hips, and other load-bearing joints.
- As adoption grows, Nanochon could help reduce the long-term healthcare burden of osteoarthritis and degenerative joint disease.
- The company’s progress highlights a broader trend: the convergence of biomechanics, regenerative medicine, and 3D printing as the future of orthopedics.
Resources & Follow-up
🔗 Selected Publications & Media
- The Memo: Nanochon Creating a New Clinical Standard for Cartilage Restoration
- Nanochon Receives Health Canada Approval for First-in-Human Trial
- 3DHEALS Interview with Benjamin Holmes
- Ben Holmes on Regenerating Cartilage (Podcast Interview)
- Nathan J. Castro – Google Scholar
- Ben Holmes – PubMed Publications
- Nathan J. Castro – PubMed Publications
🌐 Contacts
Comments